Fig. 3

In vivo assessment of dopamine release by imaging with [¹⁸F]fallypride. a Representative images displaying the uptake of [¹⁸F]fallypride in the striata of implanted (upper panel) and vehicle-treated (lower panel) rats at each of the time points studied. b, d Retention of [¹⁸F]fallypride measured by longitudinal PET imaging (~ 10 MBq, acquired from 90 to 120 min post-injection). White bars represent data from the vehicle-treated lesioned rat striata, and black bars represent data from the lesioned rat striata implanted with mDAs (n = 8, *P < 0.05, 2-way ANOVA with post hoc Bonferroni test, data shown as % change in uptake (b) or %ID/g ± SEM (d)). c, e [¹⁸F]fallypride occupancy in high- and low-TH grafts in vivo. White bars represent data from the vehicle-treated lesioned rat striata, grey bars from the lesioned striata implanted with low-TH mDAs and black bars from the lesioned striata implanted with high-TH mDAs (n = 8, 4, 4, *P < 0.05, 2-way ANOVA with post hoc Bonferroni test, data shown as % change in uptake (c) or %ID/g ± SEM (e))